semaglutide bristol tn Ozempic Weight Loss Injections & Clinics Near You ABOUT FACE MEDSPA & WELLNESS

Additional indications Knee osteoarthritis, sleep apnea, MASLD, cardiovascular outcomes, and chronic low back pain would follow based on their respective trial timelines This mirrors how Lilly handled tirzepatide: Mounjaro was approved for diabetes first (May 2022), followed by Zepbound for obesity (November 2023)

Injectable treatments may involve temporary swelling or bruising

But until now, they have largely been available in the U.S

Published results arent expected before 2028

Increased heart rate: Some participants reported accelerated heart rate, which may require monitoring, especially for those with a history of heart disease

91 However, several side effects were observed, such as accumulation of antibodies and acute pancreatitis, despite low incidences reported